Breaking News

SYBX

Synlogic

15
Jun

04/27/23 H.C. Wainwright: Synlogic assumed with a Buy at H.C. Wainwright

03/29/23 Chardan: Synlogic price target lowered to $5.50 from $7.00 at Chardan

11/11/22 Chardan: Synlogic price target lowered to $7 from $9 at Chardan

10/18/22 Chardan: Synlogic's topline data validates synthetic biotic design platform, says Chardan

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
On The Fly	Biotech Alert: Searches spiking for these stocks today » 10:37 05/11/23 05/11 10:37 05/11/23 10:37 SYBX Synlogic / + , MORF Morphic $57.28 / -0.47 (-0.81%) , VYGR Voyager Therapeutics $10.04 / +0.13 (+1.31%) , BTAI BioXcel Therapeutics $28.43 / -0.12 (-0.42%) , AXSM Axsome Therapeutics $80.50 / +0.305 (+0.38%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options VYGR SYBX MORF BTAI AXSM VYGR Voyager Therapeutics $10.04 / +0.13 (+1.31%) 03/28/23 Voyager presents new data data for AD and GBA1 gene therapy for PD treatments 03/06/23 Voyager announces Novartis exercised option to license novel capsids for $25M 01/09/23 Voyager, Neurocrine enter collaboration to advance multiple gene therapies 12/14/22 Voyager Therapeutics appoints Grace Colon to board of directors SYBX Synlogic / + 05/09/23 Synlogic granted FDA orphan drug designation for SYNB1934 03/28/23 Synlogic receives positive EMA opinion on orphan designation for SYNB1934 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria MORF Morphic $57.28 / -0.47 (-0.81%) 05/11/23 Morphic presents new biomarker data at DDW 2023 on MORF-057 05/04/23 Morphic director buys $47.25M in common stock 04/25/23 Morphic reports results from EMERALD-1 Phase 2a study of MORF-057 02/23/23 Morphic sees cash runway into 2H26 BTAI BioXcel Therapeutics $28.43 / -0.12 (-0.42%) 05/08/23 BioXcel Therapeutics announces upcoming milestones 03/09/23 BioXcel Therapeutics announces anticipated milestones 03/09/23 BioXcel Therapeutics sees cash runway into 2025 03/09/23 BioXcel Therapeutics evaluating strategic options for OnkosXcel AXSM Axsome Therapeutics $80.50 / +0.305 (+0.38%) 05/08/23 Axsome Therapeutics expects cash to fund operations into cash flow positivity 05/01/23 Axsome joins MHA, State of New York to raise awareness of mental health in May 03/10/23 Axsome Therapeutics says 'material cash deposits' with SVB, Citibank 02/27/23 Axsome Therapeutics expects cash to fund operations into cash flow positivity SYBX MORF VYGR BTAI AXSM SYBX Synlogic / + 04/27/23 H.C. Wainwright Synlogic assumed with a Buy at H.C. Wainwright 03/29/23 Chardan Synlogic price target lowered to $5.50 from $7.00 at Chardan 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan MORF Morphic $57.28 / -0.47 (-0.81%) 04/26/23 BMO Capital Morphic price target raised to $106 from $83 at BMO Capital 04/26/23 RBC Capital Morphic price target raised to $80 from $75 at RBC Capital 04/25/23 Wells Fargo Morphic price target raised to $80 from $67 at Wells Fargo 03/08/23 SVB Securities Morphic price target raised to $56 from $45 at SVB Securities VYGR Voyager Therapeutics $10.04 / +0.13 (+1.31%) 05/10/23 Canaccord Voyager Therapeutics price target raised to $14 from $10 at Canaccord 05/10/23 Truist Truist starts Voyager Therapeutics at Buy, sees 'early investors rewarded' 05/10/23 Truist Voyager Therapeutics initiated with a Buy at Truist 03/09/23 Oppenheimer Voyager Therapeutics initiated with an Outperform at Oppenheimer BTAI BioXcel Therapeutics $28.43 / -0.12 (-0.42%) 05/10/23 Mizuho BioXcel Therapeutics price target raised to $40 from $38 at Mizuho 05/09/23 Guggenheim BioXcel Therapeutics price target lowered to $46 from $50 at Guggenheim 04/13/23 Mizuho Otsuka briefing docs positive for Axsome and BioXcel, says Mizuho 03/21/23 H.C. Wainwright BioXcel Therapeutics price target lowered to $66 from $79 at H.C. Wainwright AXSM Axsome Therapeutics $80.50 / +0.305 (+0.38%) 05/11/23 Mizuho Axsome Therapeutics price target raised to $95 from $84 at Mizuho 05/09/23 Guggenheim Axsome Therapeutics price target raised to $100 from $90 at Guggenheim 05/09/23 Morgan Stanley Axsome Therapeutics price target raised to $87 from $83 at Morgan Stanley VYGR SYBX MORF BTAI AXSM VYGR Voyager Therapeutics $10.04 / +0.13 (+1.31%) 05/09/23 Voyager Therapeutics reports Q1 EPS $2.94, consensus 77c 03/07/23 Voyager Therapeutics reports Q4 EPS (61c), consensus (55c) SYBX Synlogic / + 05/11/23 Synlogic reports Q1 EPS (23c), consensus (23c) 03/29/23 Synlogic reports Q4 EPS (24c), consensus (25c) MORF Morphic $57.28 / -0.47 (-0.81%) 04/25/23 Morphic reports Q1 EPS (90c), consensus (80c) 02/23/23 Morphic reports 2022 EPS ($1.55), consensus ($1.79) BTAI BioXcel Therapeutics $28.43 / -0.12 (-0.42%) 05/08/23 BioXcel Therapeutics reports Q1 EPS ($1.84), consensus ($1.62) 03/09/23 BioXcel Therapeutics reports Q4 EPS ($1.95), consensus ($1.45) AXSM Axsome Therapeutics $80.50 / +0.305 (+0.38%) 05/08/23 Axsome Therapeutics reports Q1 EPS (26c), consnesus ($1.04) 02/27/23 Axsome Therapeutics reports Q4 EPS ($1.41), consnesus ($1.14) 03 May VYGR SYBX MORF BTAI AXSM VYGR Voyager Therapeutics $10.04 / +0.13 (+1.31%) 05/09/23 What You Missed On Wall Street On Tuesday 05/09/23 What You Missed On Wall Street This Morning SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers MORF Morphic $57.28 / -0.47 (-0.81%) 05/10/23 Biotech Alert: Searches spiking for these stocks today 05/08/23 Biotech Alert: Searches spiking for these stocks today 04/28/23 Biotech Alert: Searches spiking for these stocks today 04/25/23 What You Missed On Wall Street On Tuesday BTAI BioXcel Therapeutics $28.43 / -0.12 (-0.42%) 12/05/22 Biotech Alert: Searches spiking for these stocks today AXSM Axsome Therapeutics $80.50 / +0.305 (+0.38%) 05/08/23 What You Missed On Wall Street On Monday 05/08/23 What You Missed On Wall Street This Morning 02/27/23 Fly Intel: Pre-market Movers 02/13/23 What You Missed On Wall Street On Monday 06/01/23 Morphic Holding, Inc. 09:00 Today Axsome Therapeutics, Inc. 06/06/23 Voyager Therapeutics, Inc. 06/15/23 Synlogic, Inc. AXSM AXSM Axsome Therapeutics $80.50 / +0.305 (+0.38%) 12/12/22 AXSOME call volume above normal and directionally bullish
Earnings	Synlogic reports Q1 EPS (23c), consensus (23c) » 06:58 05/11/23 05/11 06:58 05/11/23 06:58 SYBX Synlogic / + Reports Q1 revenue $174M,… Reports Q1 revenue $174M, consensus $140K. Based upon its current operating plan and balance sheet as of March 31, 2023, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. "We continue to advance the SYNB1934 program towards initiation of our pivotal study, Synpheny-3, in the first half of the year, focused on our opportunity to transform the medical management of PKU," said Aoife Brennan,CEO. "The quarter also included recognition of Synthetic Biotics as novel biotherapeutics for rare metabolic diseases more broadly, as both our PKU and homocystinuria programs were spotlighted at the leading medical congress for inborn errors of metabolism." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SYBX Synlogic / + 05/09/23 Synlogic granted FDA orphan drug designation for SYNB1934 03/28/23 Synlogic receives positive EMA opinion on orphan designation for SYNB1934 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria SYBX Synlogic / + 04/27/23 H.C. Wainwright Synlogic assumed with a Buy at H.C. Wainwright 03/29/23 Chardan Synlogic price target lowered to $5.50 from $7.00 at Chardan 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan SYBX Synlogic / + 03/29/23 Synlogic reports Q4 EPS (24c), consensus (25c) SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers 06/15/23 Synlogic, Inc.
Hot Stocks	Synlogic granted FDA orphan drug designation for SYNB1934 » 06:55 05/09/23 05/09 06:55 05/09/23 06:55 SYBX Synlogic / + Synlogic announced that… Synlogic announced that the U.S. FDA has granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SYBX Synlogic / + 03/28/23 Synlogic receives positive EMA opinion on orphan designation for SYNB1934 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria SYBX Synlogic / + 04/27/23 H.C. Wainwright Synlogic assumed with a Buy at H.C. Wainwright 03/29/23 Chardan Synlogic price target lowered to $5.50 from $7.00 at Chardan 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan SYBX Synlogic / + 03/29/23 Synlogic reports Q4 EPS (24c), consensus (25c) 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers 05/10/23 May Micro-Cap Virtual Conference 06/15/23 Synlogic, Inc.

Over a month ago
Initiation	Synlogic assumed with a Buy at H.C. Wainwright » 06:10 04/27/23 04/27 06:10 04/27/23 06:10 SYBX Synlogic / + H.C. Wainwright analyst… H.C. Wainwright analyst Ed Arce assumed coverage of Synlogic with a Buy rating and $5 price target. Synlogic is a late-stage clinical biotech company focused on the design and development of genetically engineered therapies for both rare and common diseases, the analyst tells investors in a research note. The firm says SYNB1934 has the potential to be the first oral, non-systemic agent for phenylketonuria. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SYBX Synlogic / + 03/28/23 Synlogic receives positive EMA opinion on orphan designation for SYNB1934 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria SYBX Synlogic / + 03/29/23 Chardan Synlogic price target lowered to $5.50 from $7.00 at Chardan 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer SYBX Synlogic / + 03/29/23 Synlogic reports Q4 EPS (24c), consensus (25c) 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers 05/10/23 May Micro-Cap Virtual Conference
Recommendations	Synlogic price target lowered to $5.50 from $7.00 at Chardan » 17:27 03/29/23 03/29 17:27 03/29/23 17:27 SYBX Synlogic / + Chardan analyst Keay… Chardan analyst Keay Nakae lowered the firm's price target on Synlogic to $5.50 from $7.00 but keeps a Buy rating on the shares. The updated price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last quarter, the analyst tells investors in a research note. The firm adds however that it remains positive on Synlogic as the company has now reported positive results from three different studies during Q4: SYNB1934 in phenylketonuria, SYNB1353 in homocystinuria, and SYNB8802 in enteric hyperoxaluria. ShowHide Related Items >><< Company News Street Research Earnings On The Fly SYBX Synlogic / + 03/28/23 Synlogic receives positive EMA opinion on orphan designation for SYNB1934 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria 10/18/22 Synlogic announces positive Phase 2 results for phenylketonuria candidate SYBX Synlogic / + 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer 05/12/22 Oppenheimer Synlogic price target lowered to $6 from $7 at Oppenheimer SYBX Synlogic / + 03/29/23 Synlogic reports Q4 EPS (24c), consensus (25c) 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers
Earnings	Synlogic reports Q4 EPS (24c), consensus (25c) » 06:42 03/29/23 03/29 06:42 03/29/23 06:42 SYBX Synlogic / + Reports Q4 revenue $100K,… Reports Q4 revenue $100K, consensus $220K. Based upon its current operating plan and balance sheet as of December 31, 2022, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. "Last year was a tremendous year for Synlogic and our Synthetic Biotic platform given our three positive clinical readouts in three different diseases in the fourth quarter alone," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "We are on track to initiate Synpheny-3, the pivotal Phase 3 study for SYNB1934 in PKU, our lead program, and we were thrilled to present three data presentations - including Phase 2 PKU data as a platform presentation - at the SIMD Annual Meeting." ShowHide Related Items >><< Company News Street Research Earnings On The Fly SYBX Synlogic / + 03/28/23 Synlogic receives positive EMA opinion on orphan designation for SYNB1934 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria 10/18/22 Synlogic announces positive Phase 2 results for phenylketonuria candidate SYBX Synlogic / + 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer 05/12/22 Oppenheimer Synlogic price target lowered to $6 from $7 at Oppenheimer SYBX Synlogic / + 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers
Hot Stocks	Synlogic receives positive EMA opinion on orphan designation for SYNB1934 » 06:54 03/28/23 03/28 06:54 03/28/23 06:54 SYBX Synlogic / + Synlogic announced that… Synlogic announced that the European Medicines Agency issued a positive opinion on the company's application for orphan designation for SYNB1934 for the treatment of phenylketonuria. "We are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease," said Aoife Brennan, M.B. Ch.B., Synlogic President and CEO. "This designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year." ShowHide Related Items >><< Company News Street Research Earnings On The Fly SYBX Synlogic / + 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria 10/18/22 Synlogic announces positive Phase 2 results for phenylketonuria candidate SYBX Synlogic / + 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer 05/12/22 Oppenheimer Synlogic price target lowered to $6 from $7 at Oppenheimer SYBX Synlogic / + 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) SYBX Synlogic / + 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 Fly Intel: Pre-market Movers

Over a quarter ago
On The Fly	Biotech Alert: Searches spiking for these stocks today » 11:15 01/23/23 01/23 11:15 01/23/23 11:15 CNCE Concert Pharmaceuticals $8.30 / +0.015 (+0.18%) , SLRX Salarius Pharmaceuticals $2.71 / -0.26 (-8.75%) , BLCM Bellicum Pharmaceuticals $1.40 / +0.12 (+9.38%) , SYBX Synlogic $1.00 / -0.011 (-1.09%) , BYSI BeyondSpring $2.71 / +0.17 (+6.69%) , RHHBY Roche $40.04 / -0.19 (-0.47%) , DNA Ginkgo Bioworks $1.77 / +0.11 (+6.65%) , LLY Eli Lilly $343.66 / -2.47 (-0.71%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SYBX SLRX RHHBY LLY DNA CNCE BYSI SYBX Synlogic $1.00 / -0.011 (-1.09%) 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria 10/18/22 Synlogic announces positive Phase 2 results for phenylketonuria candidate 09/06/22 Synlogic receives milestone payment und research collaboration with Roche SLRX Salarius Pharmaceuticals $2.71 / -0.26 (-8.75%) 01/19/23 Salarius Pharmaceuticals to present SP-3164 preclinical data 01/05/23 Salarius Pharmaceuticals announces issuance of new U.S. patent 12/13/22 Salarius Pharmaceuticals presents clinical data on seclidemstat 12/13/22 Salarius Pharmaceuticals presents SP-3164 data RHHBY Roche $40.04 / -0.19 (-0.47%) 01/19/23 Roche says Phase 3 IMbrave050 study of Tecentriq-Avastin met primary endpoint 01/12/23 Roche announces EC approval of Xofluza in children aged one year and above 01/09/23 Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab 01/06/23 Genentech announces FDA acceptance of, grants priority review for glofitamab BLA LLY Eli Lilly $343.66 / -2.47 (-0.71%) 01/20/23 Eli Lilly, Boehringer: FDA accepts sNDA for Jardiance for adults with CKD 01/19/23 Eli Lilly discloses FDA complete response letter for submission of donanemab 01/12/23 California AG files suit against drugmakers, PBMs over insulin prices 01/04/23 Altimmune appoints Jordt as Chief Business Officer DNA Ginkgo Bioworks $1.77 / +0.11 (+6.65%) 01/18/23 Ginkgo Bioworks and NAMUH announce collaboration to develop HMOs 01/17/23 Ginkgo Bioworks, Xwell expand support for CDC's Genomic Surveillance program 01/17/23 Ginkgo Bioworks and Xwell partner in influenza variant detection for CDC 01/09/23 Ginkgo Bioworks, Prokarium announce RNA collaboration CNCE Concert Pharmaceuticals $8.30 / +0.015 (+0.18%) 01/19/23 Sun to acquire Concert for $8 per share of stock in cash 11/21/22 Concert Pharmaceuticals presents data from THRIVE-AA1 study 09/10/22 Concert announces presentation of CTP-543 THRIVE-AA1 Phase 3 data 08/01/22 Concert Pharma reports results for 2nd CTP-543 Phase 3 trial in Alopecia Areata BYSI BeyondSpring $2.71 / +0.17 (+6.69%) 01/09/23 BeyondSpring regains Nasdaq minimum bid price compliance 12/13/22 BeyondSpring presents plinabulin data in DIN in NSCLC patients 11/23/22 BeyondSpring receives minimum bid price requirement notice from Nasdaq 09/13/22 BeyondSpring presents new data on plinabulin CNCE SLRX BLCM SYBX BYSI RHHBY DNA LLY CNCE Concert Pharmaceuticals $8.30 / +0.015 (+0.18%) 01/20/23 JonesResearch Concert Pharmaceuticals downgraded to Hold from Buy at JonesResearch 01/19/23 Jefferies Concert Pharmaceuticals downgraded to Hold from Buy at Jefferies 01/19/23 JMP Securities Concert Pharmaceuticals downgraded to Market Perform at JMP Securities 01/19/23 Truist Concert Pharmaceuticals downgraded to Hold from Buy at Truist SLRX Salarius Pharmaceuticals $2.71 / -0.26 (-8.75%) 03/11/22 H.C. Wainwright Salarius Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright BLCM Bellicum Pharmaceuticals $1.40 / +0.12 (+9.38%) 02/16/22 Ladenburg Bellicum Pharmaceuticals initiated with a Buy at Ladenburg SYBX Synlogic $1.00 / -0.011 (-1.09%) 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer 05/12/22 Oppenheimer Synlogic price target lowered to $6 from $7 at Oppenheimer BYSI BeyondSpring $2.71 / +0.17 (+6.69%) RHHBY Roche $40.04 / -0.19 (-0.47%) 01/18/23 Deutsche Bank Deutsche Bank bearish on Roche heading into FY23, cuts to Sell 01/18/23 Deutsche Bank Roche downgraded to Sell from Hold at Deutsche Bank 01/12/23 Guggenheim Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks 01/05/23 Jefferies Roche downgraded on 'tougher 2023 catalyst path' at Jefferies DNA Ginkgo Bioworks $1.77 / +0.11 (+6.65%) 11/28/22 Berenberg Berenberg starts 'well-positioned' disruptor Ginkgo Bioworks with a Buy 11/28/22 Berenberg Ginkgo Bioworks initiated with a Buy at Berenberg 10/04/22 Morgan Stanley Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley 08/16/22 BTIG Ginkgo Bioworks price target raised to $6 from $5 at BTIG LLY Eli Lilly $343.66 / -2.47 (-0.71%) 01/20/23 William Blair Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair 01/03/23 Barclays Eli Lilly price target raised to $400 from $395 at Barclays 12/23/22 Raymond James ProQR Therapeutics price target raised to $5 from $2 at Raymond James SYBX SLRX RHHBY LLY DNA CNCE SYBX Synlogic $1.00 / -0.011 (-1.09%) 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) 08/11/22 Synlogic reports Q2 EPS (22c), consensus (23c) SLRX Salarius Pharmaceuticals $2.71 / -0.26 (-8.75%) 11/10/22 Salarius Pharmaceuticals reports Q3 EPS ($6.41) vs ($2.09) last year 08/08/22 Salarius Pharmaceuticals reports Q2 EPS (9c) vs (7c) last year RHHBY Roche $40.04 / -0.19 (-0.47%) 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year LLY Eli Lilly $343.66 / -2.47 (-0.71%) 12/13/22 Eli Lilly sees FY23 EPS $8.10-$8.30, consensus $9.15 12/13/22 Eli Lilly backs FY22 EPS view $7.70-$7.85, consensus $7.78 11/01/22 Eli Lilly cuts FY22 EPS view to $7.70-$7.85 from $7.90-$8.05, consensus $7.99 11/01/22 Eli Lilly reports Q3 EPS $1.98, consensus $1.96 DNA Ginkgo Bioworks $1.77 / +0.11 (+6.65%) 01/11/23 Ginkgo Bioworks backs FY22 revenue view $460M-$480M, consensus $470.79M 11/14/22 Ginkgo Bioworks sees FY22 revenue $425M-$440M, consensus $435.34M 11/14/22 Ginkgo Bioworks reports Q3 EPS (41c), consensus (30c) 08/15/22 Ginkgo Bioworks raises FY22 revenue view to $425M-$440M from $375M-$390M CNCE Concert Pharmaceuticals $8.30 / +0.015 (+0.18%) 11/07/22 Concert Pharmaceuticals reports Q3 EPS (58c), consensus (59c) 08/04/22 Concert Pharmaceuticals reports Q2 EPS (59c), consensus (85c) 16 Nov 02 Jun RHHBY LLY RHHBY Roche $40.04 / -0.19 (-0.47%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports LLY Eli Lilly $343.66 / -2.47 (-0.71%) 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 08/13/22 Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says SLRX RHHBY LLY DNA CNCE BYSI SLRX Salarius Pharmaceuticals $2.71 / -0.26 (-8.75%) 10/07/22 Biotech Alert: Searches spiking for these stocks today RHHBY Roche $40.04 / -0.19 (-0.47%) 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today LLY Eli Lilly $343.66 / -2.47 (-0.71%) 01/20/23 What You Missed On Wall Street This Morning 01/20/23 Fly Intel: Pre-market Movers 12/19/22 What You Missed On Wall Street On Monday DNA Ginkgo Bioworks $1.77 / +0.11 (+6.65%) 01/11/23 What You Missed On Wall Street On Wednesday 01/11/23 What You Missed On Wall Street This Morning 12/30/22 What You Missed On Wall Street On Friday CNCE Concert Pharmaceuticals $8.30 / +0.015 (+0.18%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/19/23 What You Missed On Wall Street On Thursday 01/19/23 What You Missed On Wall Street This Morning 01/19/23 Fly Intel: Pre-market Movers BYSI BeyondSpring $2.71 / +0.17 (+6.69%) 12/15/22 Biotech Alert: Searches spiking for these stocks today 01/24/23 Next Generation Ophthalmic Drug Delivery Summit 02/24/23 Annual Meeting of AAAAI 2023 02/25/23 16th Int'l Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 02/02/23 Roche - RHHBY 02/02/23 Eli Lilly - LLY LLY DNA LLY Eli Lilly $343.66 / -2.47 (-0.71%) 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish 09/28/22 Early notable gainers among liquid option names on September 28th 09/28/22 Unusually active option classes on open September 28th DNA Ginkgo Bioworks $1.77 / +0.11 (+6.65%) 11/14/22 Ginkgo Bioworks options imply 12.3% move in share price post-earnings 09/22/22 Largest borrow rate increases among liquid names 09/20/22 Largest borrow rate increases among liquid names 09/12/22 Largest borrow rate increases among liquid names
On The Fly	Fly Intel: Pre-market Movers » 08:54 01/19/23 01/19 08:54 01/19/23 08:54 CVAC CureVac $9.49 / -0.285 (-2.92%) , SYBX Synlogic $1.01 / -0.0192 (-1.86%) , PG Procter & Gamble $145.48 / -4.08 (-2.73%) , AA Alcoa $53.43 / -1.48 (-2.70%) , ALL Allstate $132.38 / -3.1 (-2.29%) , DFS Discover $102.26 / -3.155 (-2.99%) , KEY KeyCorp $17.24 / -0.775 (-4.30%) , RBLX Roblox $35.76 / -1.36 (-3.66%) , CNCE Concert Pharmaceuticals $6.88 / -0.51 (-6.90%) Check out this morning's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SYBX RBLX PG KEY DFS CVAC CNCE ALL AA SYBX Synlogic $1.01 / -0.0192 (-1.86%) 01/19/23 Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria 10/18/22 Synlogic announces positive Phase 2 results for phenylketonuria candidate 09/06/22 Synlogic receives milestone payment und research collaboration with Roche RBLX Roblox $35.76 / -1.36 (-3.66%) 01/19/23 Roblox falls 7% to $33.33 in pre-market after Morgan Stanley downgrade 01/18/23 Roblox CEO says community grew 23% in 2022 to over 56M daily users 01/17/23 Roblox rises 12.6% 01/17/23 Roblox rises 11.2% PG Procter & Gamble $145.48 / -4.08 (-2.73%) 01/19/23 Procter & Gamble says Q2 growth broad based across business units 01/19/23 Procter & Gamble reports Q2 gross margin down 160 bps vs. a year ago 01/19/23 Procter & Gamble CEO says 'very difficult cost and operating environment' 01/19/23 Procter & Gamble backs FY23 CapEx view approximately 5% of fiscal 2023 net sales KEY KeyCorp $17.24 / -0.775 (-4.30%) 01/19/23 KeyCorp sees FY23 NII up 6%-9%, noninterest income down 1%-3% 01/19/23 KeyCorp reiterates long-term targets 12/14/22 KeyCorp raises prime lending rate to 7.5% from 7.00%, effective December 15 11/17/22 KeyCorp CFO Donald Kimble retiring, Chief Strategy Officer Clark Khayat succeeds DFS Discover $102.26 / -3.155 (-2.99%) 01/19/23 Discover sees FY23 NIM modestly higher vs. FY22 01/17/23 Cantaloupe appoints Novoseletsky as Chief Legal, Compliance Officer 11/16/22 Discover up 4% after announcing plans to resume stock repurchases 10/24/22 Discover reports Q3 net charge-off rate 1.71% CVAC CureVac $9.49 / -0.285 (-2.92%) 01/09/23 CureVac appoints Alexander Zehnder as CEO 01/06/23 CureVac announces data on joint COVID-19, Flu mRNA vaccine programs 11/16/22 CureVac, GSK teamed on 4 Phase 1 studies in COVID-19 and flu vaccines 11/16/22 CureVac reports cash equivalents position of EUR 540.9M at September-end CNCE Concert Pharmaceuticals $6.88 / -0.51 (-6.90%) 01/19/23 Sun to acquire Concert for $8 per share of stock in cash 11/21/22 Concert Pharmaceuticals presents data from THRIVE-AA1 study 09/10/22 Concert announces presentation of CTP-543 THRIVE-AA1 Phase 3 data 08/01/22 Concert Pharma reports results for 2nd CTP-543 Phase 3 trial in Alopecia Areata ALL Allstate $132.38 / -3.1 (-2.29%) 12/23/22 Allstate announces zero net emissions commitment by 2030 12/15/22 Allstate implements auto insurance rates for November 11/29/22 Allstate names Christine DeBiase chief legal officer 11/17/22 Allstate announces 14% rate increases across 15 locations in October AA Alcoa $53.43 / -1.48 (-2.70%) 01/18/23 Alcoa falls 4% to $51.50 after Q4 results and guidance 01/18/23 Alcoa sees FY23 total alumina shipments at 12.7M-12.9M mt 01/18/23 Alcoa reports Q4 adjusted EBITDA $29M vs. $210M in Q3 01/10/23 Alcoa restructures executive team with Oplinger to COO, Beerman to CFO jobs CVAC SYBX PG AA ALL DFS KEY RBLX CNCE CVAC CureVac $9.49 / -0.285 (-2.92%) 01/19/23 UBS UBS upgrades CureVac after 'major milestone and clearing event' 01/19/23 UBS CureVac upgraded to Buy from Neutral at UBS 01/09/23 Jefferies CureVac upgraded to Buy at Jefferies after mRNA platform validation 01/09/23 Jefferies CureVac upgraded to Buy from Hold at Jefferies SYBX Synlogic $1.01 / -0.0192 (-1.86%) 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer 05/12/22 Oppenheimer Synlogic price target lowered to $6 from $7 at Oppenheimer PG Procter & Gamble $145.48 / -4.08 (-2.73%) 01/13/23 JPMorgan Procter & Gamble price target raised to $150 from $141 at JPMorgan 12/06/22 Deutsche Bank Procter & Gamble price target raised to $162 from $156 at Deutsche Bank 11/22/22 Jefferies Procter & Gamble price target raised to $164 from $149 at Jefferies 11/22/22 Wolfe Research Procter & Gamble initiated with an Outperform at Wolfe Research AA Alcoa $53.43 / -1.48 (-2.70%) 01/19/23 Citi Alcoa price target raised to $55 from $45 at Citi 01/19/23 B. Riley Alcoa price target raised to $42 from $41 at B. Riley 01/19/23 BMO Capital Alcoa price target lowered to $50 from $55 at BMO Capital 12/09/22 Morgan Stanley Alcoa downgraded to Equal Weight from Overweight at Morgan Stanley ALL Allstate $132.38 / -3.1 (-2.29%) 01/19/23 Evercore ISI Allstate price target lowered to $144 from $151 at Evercore ISI 01/19/23 Citi Allstate price target lowered to $150 from $160 at Citi 01/10/23 UBS Allstate price target raised to $160 from $150 at UBS 01/10/23 Piper Sandler Allstate price target raised to $153 from $147 at Piper Sandler DFS Discover $102.26 / -3.155 (-2.99%) 01/06/23 Barclays Discover downgraded to Equal Weight from Overweight at Barclays 12/15/22 Wells Fargo Discover price target raised to $115 from $103 at Wells Fargo 12/13/22 BofA Synchrony downgraded to Neutral at BofA on consumer concerns 12/13/22 BofA Discover double downgraded to Underperform at BofA on consumer concerns KEY KeyCorp $17.24 / -0.775 (-4.30%) 01/10/23 Odeon Capital KeyCorp upgraded to Buy from Hold at Odeon Capital 01/06/23 Deutsche Bank KeyCorp price target lowered to $20 from $23 at Deutsche Bank 01/03/23 Barclays KeyCorp upgraded to Equal Weight from Underweight at Barclays 12/21/22 DA Davidson DA Davidson starts KeyCorp with a Buy, sees levers to grow earnings in 2023 RBLX Roblox $35.76 / -1.36 (-3.66%) 01/19/23 Morgan Stanley Roblox downgraded to Underweight from Equal Weight at Morgan Stanley 01/19/23 Morgan Stanley Roblox downgraded to Underweight from Equal Weight at Morgan Stanley 01/18/23 Needham Roblox price target raised to $42 from $39 at Needham 01/18/23 BTIG Roblox December outperformance due to core monetization, gift cards, says BTIG CNCE Concert Pharmaceuticals $6.88 / -0.51 (-6.90%) 09/13/22 Truist Concert Pharmaceuticals price target raised to $25 from $22 at Truist 09/13/22 Truist AnaptysBio cut to Hold at Truist with price target of $28 08/24/22 JonesResearch Concert Pharmaceuticals initiated with a Buy at JonesTrading 08/01/22 Jefferies Concert Pharmaceuticals price target raised to $14 from $9.50 at Jefferies SYBX RBLX PG KEY DFS CVAC CNCE ALL AA SYBX Synlogic $1.01 / -0.0192 (-1.86%) 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) 08/11/22 Synlogic reports Q2 EPS (22c), consensus (23c) RBLX Roblox $35.76 / -1.36 (-3.66%) 11/09/22 Roblox reports Q3 EPS (50c), consensus (33c) 11/08/22 Notable companies reporting before tomorrow's open 08/09/22 Roblox reports Q2 EPS (30c), consensus (23c) PG Procter & Gamble $145.48 / -4.08 (-2.73%) 01/19/23 Procter & Gamble raises FY23 sales growth outlook 01/19/23 Procter & Gamble reports Q2 core EPS $1.59, consensus $1.59 01/18/23 Notable companies reporting before tomorrow's open KEY KeyCorp $17.24 / -0.775 (-4.30%) 01/19/23 KeyCorp reports Q4 EPS 38c, consensus 54c 10/20/22 KeyCorp reports Q3 EPS 55c, consensus 58c DFS Discover $102.26 / -3.155 (-2.99%) 01/18/23 Discover reports Q4 EPS $3.77, consensus $3.66 01/18/23 Notable companies reporting after market close 10/24/22 Discover Financial reports Q3 EPS $3.54, consensus $3.72 10/24/22 Notable companies reporting after market close CVAC CureVac $9.49 / -0.285 (-2.92%) 08/18/22 CureVac reports Q2 revenue EUR 20.1M vs. EUR 22.4M last year CNCE Concert Pharmaceuticals $6.88 / -0.51 (-6.90%) 11/07/22 Concert Pharmaceuticals reports Q3 EPS (58c), consensus (59c) 08/04/22 Concert Pharmaceuticals reports Q2 EPS (59c), consensus (85c) ALL Allstate $132.38 / -3.1 (-2.29%) 01/18/23 Allstate sees Q4 net loss $335M-$385M 11/02/22 Allstate reports Q3 adjusted EPS ($1.56), consensus ($1.52) 11/02/22 Notable companies reporting after market close 10/19/22 Allstate sees Q3 adjusted net loss ($450M)-($400M) AA Alcoa $53.43 / -1.48 (-2.70%) 01/18/23 Alcoa reports Q4 adjusted EPS (70c), consensus (85c) 10/19/22 Alcoa reports Q3 EPS (33c), consensus 19c 10/19/22 Notable companies reporting after market close 07/20/22 Alcoa reports Q2 adjusted EPS $2.67, consensus $2.31 02 Jun RBLX PG ALL AA RBLX Roblox $35.76 / -1.36 (-3.66%) 01/18/23 Video game sales fell 13% y/y in Europe in December, GI.biz says 12/28/22 Kids scamming kids on Roblox, IGN reports 11/30/22 Roblox nabs Apple executive for key engineering role, Axios reports 10/06/22 Roblox sued by watchdog group over girl's exploitation, Bloomberg reports PG Procter & Gamble $145.48 / -4.08 (-2.73%) 10/17/22 Procter & Gamble bets inflation won't push shoppers to swap brands, WSJ reports 10/10/22 Environmentalists to challenge P&G CEO as chairman, Reuters says ALL Allstate $132.38 / -3.1 (-2.29%) 12/05/22 Allstate replacing Accenture's Droga5 for creative account, AdAge reports AA Alcoa $53.43 / -1.48 (-2.70%) 12/17/22 Amazon, Google among Barron's 10 favorite stocks for 2023 10/15/22 BHP among mining stocks with bright long-term outlook, Barron's says 10/12/22 White House weighing ban on Russian aluminum, Bloomberg says 09/29/22 LME launching discussion paper on possible Russian metal ban, Bloomberg reports RBLX PG KEY DFS CVAC ALL AA RBLX Roblox $35.76 / -1.36 (-3.66%) 12/23/22 Buy/Sell: Wall Street's top 10 stock calls this week 12/21/22 What You Missed On Wall Street On Wednesday 12/21/22 What You Missed On Wall Street This Morning PG Procter & Gamble $145.48 / -4.08 (-2.73%) 11/26/22 Buy/Sell: Wall Street's top 10 stock calls this week 11/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/19/22 What You Missed On Wall Street On Wednesday 10/19/22 What You Missed On Wall Street This Morning KEY KeyCorp $17.24 / -0.775 (-4.30%) 12/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/20/22 Fly Intel: Pre-market Movers DFS Discover $102.26 / -3.155 (-2.99%) 12/17/22 Buy/Sell: Wall Street's top 10 stock calls this week 12/13/22 What You Missed On Wall Street On Tuesday 12/13/22 What You Missed On Wall Street This Morning CVAC CureVac $9.49 / -0.285 (-2.92%) 01/09/23 What You Missed On Wall Street On Monday 01/09/23 What You Missed On Wall Street This Morning ALL Allstate $132.38 / -3.1 (-2.29%) 10/20/22 What You Missed On Wall Street This Morning 08/03/22 Fly Intel: After-Hours Movers AA Alcoa $53.43 / -1.48 (-2.70%) 01/18/23 Fly Intel: After-Hours Movers 12/12/22 Fly Insider: comScore, Donegal Group among week's notable insider trades 12/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 10/20/22 What You Missed On Wall Street On Thursday 01/19/23 January Virtual Micro-Cap Conference 01/19/23 Discover - DFS 01/19/23 Procter & Gamble - PG 01/19/23 KeyCorp - KEY 02/02/23 Allstate - ALL 02/15/23 Roblox - RBLX RBLX PG KEY DFS ALL AA RBLX Roblox $35.76 / -1.36 (-3.66%) 12/27/22 Roblox call volume above normal and directionally bullish 10/18/22 Notable open interest changes for October 18th 10/17/22 Unusually active option classes on open October 17th 10/06/22 Roblox Corp put volume heavy and directionally bearish PG Procter & Gamble $145.48 / -4.08 (-2.73%) 01/11/23 Largest borrow rate increases among liquid names 11/21/22 Unusually active option classes on open November 21st 10/19/22 Unusually active option classes on open October 19th 10/10/22 Procter & Gamble put volume heavy and directionally bearish KEY KeyCorp $17.24 / -0.775 (-4.30%) 10/21/22 Early notable gainers among liquid option names on October 21st DFS Discover $102.26 / -3.155 (-2.99%) 01/18/23 Discover options imply 4.3% move in share price post-earnings 01/09/23 Discover put volume heavy and directionally bearish 12/19/22 Discover put volume heavy and directionally bearish 11/16/22 Early notable gainers among liquid option names on November 16th ALL Allstate $132.38 / -3.1 (-2.29%) 10/21/22 Unusually active option classes on open October 21st AA Alcoa $53.43 / -1.48 (-2.70%) 01/18/23 Alcoa options imply 6.3% move in share price post-earnings 12/30/22 Unusually active option classes on open December 30th 11/28/22 Unusually active option classes on open November 28th 10/28/22 Alcoa call volume above normal and directionally bullish
Hot Stocks	Synlogic's SYNB1934 granted Rare Pediatric Disease Designation by FDA » 07:00 01/19/23 01/19 07:00 01/19/23 07:00 SYBX Synlogic $1.01 / -0.0192 (-1.86%) Synlogic announced that… Synlogic announced that SYNB1934 was granted Rare Pediatric Disease Designation by the FDA for the potential treatment of phenylketonuria. The company expects to initiate Synpheny-3, the pivotal Phase 3 study for SYNB1934 in PKU in the first half of the year. Synlogic also received RPDD for SYNB1353 for the potential treatment of homocystinuria in December 2022. ShowHide Related Items >><< Company News Street Research Earnings Events SYBX Synlogic $1.01 / -0.0192 (-1.86%) 12/15/22 Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria 10/18/22 Synlogic announces positive Phase 2 results for phenylketonuria candidate 09/06/22 Synlogic receives milestone payment und research collaboration with Roche 08/23/22 Synlogic granted FDA Fast Track designation for SYNB1353 SYBX Synlogic $1.01 / -0.0192 (-1.86%) 11/11/22 Chardan Synlogic price target lowered to $7 from $9 at Chardan 10/18/22 Chardan Synlogic's topline data validates synthetic biotic design platform, says Chardan 10/18/22 Oppenheimer Synlogic price target raised to $8 from $6 at Oppenheimer 05/12/22 Oppenheimer Synlogic price target lowered to $6 from $7 at Oppenheimer SYBX Synlogic $1.01 / -0.0192 (-1.86%) 11/10/22 Synlogic reports Q3 EPS (25c), consensus (23c) 08/11/22 Synlogic reports Q2 EPS (22c), consensus (23c) 01/19/23 January Virtual Micro-Cap Conference

On The Fly

News and insights, exclusive to thefly.com

11:00	Biotech Alert: Searches spiking for these stocks today»
10:28	Here's What You Missed in Crypto This Week»
09:38	Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations»
08:59	Fly Intel: Pre-market Movers»
19:09	Fly Intel: After-Hours Movers»

View all On The Fly Stories »

Upcoming
Events (10)

AUTL ...	Truist Hosted Company Events at 2023 ASCO Annual Meeting
A ...	2023 ASCO Annual Meeting
LICY	Li-Cycle
MXL	MaxLinear
GERN	Geron
	Consumer Retail & Lifestyle Brands
	Healthcare
TERN	Biotechnology--Reception
YJ	Yunji - YJ
WDH	Waterdrop - WDH

View all of today’s events »

Today’s
Syndicate (1)

MKSI	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial